Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ.
Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30.
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM.
Gynecol Oncol. 2020 Mar;156(3):715-725. doi: 10.1016/j.ygyno.2019.12.033. Epub 2020 Jan 20.
HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N.
Int J Gynecol Pathol. 2021 Jan;40(1):17-23. doi: 10.1097/PGP.0000000000000711.
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952.
Ovarian cancer metastasis: Looking beyond the surface.
Bayraktar E, Chen S, Corvigno S, Liu J, Sood AK.
Cancer Cell. 2024 Oct 14;42(10):1631-1636. doi: 10.1016/j.ccell.2024.08.016. Epub 2024 Sep 12.
Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y, Tan Y, Zhou D, Bai Y, Cao T, Zhong C, Huang W, Ou Y, Guo L, Liu Q, Yin D, Chen L, Luo X, Sun D, Sheng X.
Front Immunol. 2022 Jul 22;13:923194. doi: 10.3389/fimmu.2022.923194. eCollection 2022.
Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA.
Int J Gynecol Cancer. 2020 Oct;30(10):1619-1626. doi: 10.1136/ijgc-2019-000832. Epub 2019 Nov 27.
Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
Angarita AM, Cholakian D, Fader AN.
Expert Rev Anticancer Ther. 2015;15(8):893-9. doi: 10.1586/14737140.2015.1052411. Epub 2015 Jun 3.
Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
Vyhlídalová Kotrbová A, Gömöryová K, Mikulová A, Plešingerová H, Sladeček S, Kravec M, Hrachovinová Š, Potěšil D, Dunsmore G, Blériot C, Bied M, Kotouček J, Bednaříková M, Hausnerová J, Minář L, Crha I, Felsinger M, Zdráhal Z, Ginhoux F, Weinberger V, Bryja V, Pospíchalová V.
J Extracell Vesicles. 2024 Mar;13(3):e12420. doi: 10.1002/jev2.12420.
Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Goff BA.
Gynecol Oncol. 2005 Sep;98(3):341-3. doi: 10.1016/j.ygyno.2005.07.006.
